Understanding the Sacubitril Hemicalcium Salt Market Opportunity

Sacubitril Valsartan Sodium, commercially known as Entresto® (Novartis brand name, scientifically referenced as LCZ696), is widely documented in public pharmaceutical literature as the first-in-class angiotensin receptor neprilysin inhibitor (ARNI). This drug substance exists as a 1:1 molar ratio co-crystal of Sacubitril and Valsartan. Within its synthetic route, Sacubitril Calcium (also referred to commercially as sacubitril hemicalcium salt, CAS 1369773-39-6) serves as a key advanced intermediate for Sacubitril Valsartan Sodium co-crystal manufacturing, as well as a building block for research and development of proprietary new chemical entities (NCEs), including candidates such as Sacubitril Alisartan Calcium.

Timing of supplier selection for this intermediate carries notable commercial significance. According to public patent database records, the core U.S. composition patent for this molecule expired in July 2023, while the relevant Chinese compound patent is scheduled to expire in 2026. This creates a well-recognized window of opportunity ahead of broad generic market entry. During this period, generic pharmaceutical developers, innovator supply chain partners and CDMO teams are actively sourcing qualified, dependable, cost-effective Sacubitril Calcium to support R&D activities, regulatory dossier preparation and pre-commercial inventory planning.

Why Manufacturer Comparison Requires Looking Beyond a Single Intermediate

Buyers evaluating Sacubitril hemicalcium salt suppliers often find that the intermediate cannot be assessed in isolation. The synthetic pathway for Sacubitril Valsartan Sodium follows a sequential workflow of upstream building blocks, including a chiral starting material (CAS 1426129-50-1), a Wittig reagent used for olefination (CAS 5717-37-3), an unsaturated intermediate generated after Wittig coupling (CAS 1012341-48-8), a saturated chiral intermediate obtained post-hydrogenation (CAS 1012341-50-2), and a deprotected chiral amine intermediate (CAS 149690-12-0). These precursors feed into Sacubitril Calcium synthesis, and ultimately support production of the finished Sacubitril Valsartan Sodium API.

A supplier that only provides the hemicalcium salt, without mastery of upstream synthetic steps, shifts the burden of multi-vendor coordination to the buyer. Fragmented sourcing tends to raise procurement overhead and introduces process consistency risks across handovers between different manufacturers with separate quality control frameworks. Shandong Tianming Pharmaceutical Group addresses this supply-chain gap by offering a full product ladder covering starting materials, advanced intermediates and the final Sacubitril Valsartan Sodium API, managed under a unified technical and quality system. This integrated product portfolio is designed to reduce coordination challenges commonly associated with sourcing from multiple separate vendors.

Quality Specifications as a Core Evaluation Metric

Among procurement teams for pharmaceutical raw materials, quality stability is consistently prioritized alongside pricing. For Sacubitril Calcium specifically, critical quality attributes include individual impurity profiles, chiral purity, consistent stoichiometric ratio for downstream Sacubitril-Valsartan co-crystal formation, residual solvent levels, particle size distribution and crystal form control.

As reported by Shandong Tianming Pharmaceutical Group, its Sacubitril Calcium material meets specifications with individual single impurity below 0.1% and chiral purity above 99.5%. These specifications are maintained via registration-oriented quality control workflows spanning incoming raw material inspection, in-process testing and finished batch release. The group also maintains rigorous monitoring for the Sacubitril-to-Valsartan ratio, chiral impurities, residual solvents, particle characteristics and crystal form — parameters that strongly influence successful co-crystal formation in downstream processing.

Production Scale and Regulatory Documentation

Production scalability forms a second key dimension for supplier due diligence. Shandong Tianming Pharmaceutical Group operates three coordinated production  and over 160 reactor vessels in aggregate, supporting multi-hundred-ton annual capacity. This setup supports supply from gram-scale R&D lots, pilot validation batches through to commercial ton-scale orders, enabling customers to retain the same supplier as their projects move from lab development to commercialization.

Complete documentation packages are equally valuable for teams preparing regulatory submissions. The company supplies full Certificates of Analysis (COA), Methods of Analysis (MOA), impurity profile characterizations and stability study data. These records can be leveraged by customers to compile dossiers for global regulatory filings including DMF and CEP. For developers building submission packages ahead of the 2026 Chinese patent expiry, comprehensive documentation streamlines the supplier qualification workflow.

Independent Process Development and Route Scalability

Beyond analytical specifications, the underlying process development history underpins long-term supply reliability. Shandong Tianming Pharmaceutical Group states that its synthetic route for this product series has been independently developed, iteratively optimized and validated for industrial scale-up. Lab-scale synthetic routes frequently exhibit different performance characteristics when transferred to large-volume production, which can lead to batch-to-batch variability. Route optimization completed prior to scale transfer is intended to mitigate such risks and support the consistent batch performance expected for regulatory-grade pharma supply.

Service Model: Technical Support Beyond Quotation

Intermediate procurement is typically an ongoing collaborative relationship rather than a one-off transaction, making post-order support a meaningful factor in supplier comparison. Shandong Tianming Pharmaceutical Group adopts a dual-support model pairing dedicated account managers with in-house technical engineers. Standard technical inquiries receive reference guidance within 2 working hours, and complex technical issues are summarized in formal written reports within 24 hours. In-stock items are generally shipped within 7–15 working days following order confirmation, quality review, packaging and logistics arrangement. Lead times for custom synthesis orders depend on synthetic complexity, workshop scheduling and raw material availability; expedited arrangements can be discussed for urgent projects.

Company Foundation for Supply Continuity

Shandong Tianming Pharmaceutical Group traces its origins to Shandong Sihuan Pharmaceutical Co., Ltd., established in 2010, with the formal group structure launched in 2020. The group runs two R&D centers in Jinan and Nanjing with more than 6,000 square meters of laboratory space and an in-house R&D team exceeding 100 staff. Annual R&D investment accounts for over 10% of revenue, compared with an industry average of approximately 5%. R&D activities are managed under an IPD integrated product development system, supported by CRM, ERP and BPM digital platforms for order tracking, inventory management and production scheduling.

Multiple group entities hold National High-Tech Enterprise status. Shandong Sihuan and Guangxi Tianming facilities maintain ISO9001 Quality Management System certification. The group has built a global customer network covering domestic pharmaceutical clusters and partners across more than 30 countries and regions.

A Practical Framework for Supplier Evaluation

For buyers benchmarking Sacubitril hemicalcium salt suppliers ahead of the 2026 patent transition window, core evaluation criteria include impurity and chiral purity profiles, access to a full upstream intermediate chain rather than only the isolated hemicalcium salt, scalable production capacity to match commercial demand, documentation suitable for DMF / CEP dossier preparation, and structured, responsive technical support. Shandong Tianming Pharmaceutical Group offers its capabilities across all these areas within its Sacubitril Valsartan Sodium and intermediates portfolio, with its full-chain supply model designed to resolve coordination burdens faced by generic and CDMO customers preparing for this therapeutic segment’s patent expiry cycle.

Home

Tianming Pharmaceutical Group